uniQure N.V. Stock price

Equities

QURE

NL0010696654

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.2 USD -3.88% Intraday chart for uniQure N.V. +0.19% -23.19%
Sales 2024 * 55.52M 59.83M Sales 2025 * 81.03M 87.32M Capitalization 230M 248M
Net income 2024 * -202M -218M Net income 2025 * -182M -196M EV / Sales 2024 * 3.14 x
Net cash position 2024 * 55.78M 60.11M Net cash position 2025 * 50.83M 54.78M EV / Sales 2025 * 2.21 x
P/E ratio 2024 *
-1.21 x
P/E ratio 2025 *
-1.42 x
Employees 480
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.12%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on uniQure N.V.

1 day-3.88%
1 week+0.19%
Current month-9.57%
1 month-22.27%
3 months-23.87%
6 months-23.42%
Current year-23.19%
More quotes
1 week
5.16
Extreme 5.16
5.45
1 month
4.76
Extreme 4.76
5.98
Current year
4.76
Extreme 4.76
7.12
1 year
4.76
Extreme 4.76
22.48
3 years
4.76
Extreme 4.76
38.80
5 years
4.76
Extreme 4.76
82.49
10 years
4.72
Extreme 4.72
82.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 14-12-31
Director of Finance/CFO 51 14-12-31
Chief Operating Officer 52 21-05-16
Members of the board TitleAgeSince
Director/Board Member 72 20-06-16
Director/Board Member 80 16-06-14
Director/Board Member 61 17-09-13
More insiders
Date Price Change Volume
24-03-28 5.2 -3.88% 767,714
24-03-27 5.41 +1.69% 600,721
24-03-26 5.32 -0.56% 447,312
24-03-25 5.35 +1.33% 446,239
24-03-22 5.28 +1.73% 519,430

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company's lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington's disease is in Phase I/II clinical study.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.814 EUR
Average target price
20.3 EUR
Spread / Average Target
+321.70%
Consensus
  1. Stock
  2. Equities
  3. Stock uniQure N.V. - Nasdaq